« Back
Home /
Apitolisib (GDC-0980)

Apitolisib (GDC-0980)

Item no.	M1727-200mg
Manufacturer	AbMole
CASRN	1032754-93-0
Amount	200mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Breast Cancer
Type	Inhibitors
Specific against	other
Purity	1
Citations	Preclinical Assessment of the Absorption and Disposition of the Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor GDC-0980 and Prediction of Its Pharmacokinetics and Efficacy in Human. Salphati, et al . Drug Metab Dispos. 2012 Sep,40(9):1785-96. PMID: 22696419 . GDC-0980 is a novel class I PI3K/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway. Wallin, et al . Mol Cancer Ther. 2011 Dec,10(12):2426-36. PMID: 21998291 . Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer. Sutherlin, et al . J Med Chem. 2011 Nov 10,54(21):7579-87. PMID: 21981714 .
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	RG7422; GNE 390
Similar products	GDC-0980, RG7422
Available
Molecular Weight	498, 6
Solubility	DMSO 15 mg/mL
Bioactivity information	Apitolisib (GDC-0980; GNE 390; RG 7422) is a potent, highly selective, oral, dual inhibitor of class I PI3K and mTOR.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

M1727-200mg-safety-datasheet.pdf